National Institutes of Health, HHS.
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Mevox, Ltd., located in Rugby, United Kingdom.
Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before June 2, 2021 will be considered.
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Daniel Lee, J.D., Technology Transfer and Patent Specialist, National Institute of Allergy and Infectious Diseases Technology Transfer and Intellectual Property Office by email (email@example.com) or phone (301-761-6327).
Start Supplemental Information
E-153-2019: Mumps and Measles Virus Immunogens and Their Use
1. United States Provisional Patent Application No. 62/946,902, filed 11 December 2019 (HHS Reference No. E-153-2019-0-US-01); and
2. International Patent Application No. PCT/US2020/064619, filed 11 December 2020 (HHS Reference No. E-153-2019-0-PCT-01).
The patent and patent application rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and the fields of use may be limited to the following: Development, commercialization, and use of protein-based vaccines expressing recombinant measles and mumps immunogens for human use to prevent measles and/or mumps infections, disease, and transmission.
This technology discloses the pre-fusion-stabilized recombinant MeV F glycoprotein trimers and MuV F glycoprotein trimers, as well as MuV prefusion F-HN chimeras for use as vaccines.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent commercialization license. In response to this notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.
End Supplemental Information
Dated: May 12, 2021.
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-10469 Filed 5-17-21; 8:45 am]
BILLING CODE 4140-01-P